Results 51 to 60 of about 429,758 (251)
Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?
Biomolecules, 2017 Intense efforts have been made by both industry and academia over the last three decades to produce viable hemoglobin (Hb)-based oxygen carriers (HBOCs), also known as “blood substitutes”.
A. Alayash
semanticscholar +1 more source
Acetylation of Sickle Cell Hemoglobin by Aspirin [PDF]
Proceedings of the National Academy of Sciences, 1973 Incubation of HbS (or HbA) with aspirin leads to incorporation of acetyl groups into the protein. Incorporation was followed by the use of aspirin labeled with 14 C in the acetyl group. The acetylated hemoglobins show an increase in oxygen affinity compared to the parent proteins.
I M, Klotz, J W, Tam
openaire +2 more sources
Crystal Structure of Carbonmonoxy Sickle Hemoglobin in R-state Conformation
Journal of Structural Biology, 2015 The fundamental pathophysiology of sickle cell disease is predicated by the polymerization of deoxygenated (T-state) sickle hemoglobin (Hb S) into fibers that distort red blood cells into the characteristic sickle shape.
M. Ghatge +7 more
semanticscholar +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT The medical burdens of sickle cell disease (SCD) and transfusion‐dependent β‐thalassemia (TDT) are chronic and cumulative, even in children. Yet the effects expand beyond medications and healthcare visits due to their impacts on school attendance, academic performance, and peer engagement.
Mary Ann Etling +2 more
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye +33 more
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola +4 more
wiley +1 more source
Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
American Society of Nephrology. Clinical Journal, 2016 BACKGROUND AND OBJECTIVES Sickle cell disease (SCD) is an inherited anemia that afflicts millions worldwide. Kidney disease is a major contributor to its morbidity and mortality.
P. Drawz +7 more
semanticscholar +1 more source
MN•CS•IO System: Cross‐Species Study for HBB Function in High‐Altitude Hypoxia Adaptation
Advanced Science, EarlyView.We developed an integrative mesh‐nanorod sorting, chitosan nanoparticle delivery, and intraosseous injection (MN•CS•IO) system to investigate HBB in high‐altitude hypoxia adaptation. Transplanting Tibetan animals' HBB‐modified Lin‐ cells into mice achieved 95.59% transfection efficiency and 8.15% HBB expression. High‐altitude HBB recipients upregulated
Wenqiao Hui +18 more
wiley +1 more source
The Fabulous Impact of CRISPR Method in Sickle Cell Disease Treatment
Trends in Peptide and Protein Sciences, 2021 Sickle cell diseases are the most prevalent monogenic blood diseases with complications such as severe end-organ harm, pain, and reduced life expectancy. Dealing options for sickle cell diseases are inadequate, as there are just two FDA-approved drugs to
Vida Ebrahimi, Atieh Hashemi
doaj +1 more source
Therapeutic Strategies to Alter Oxygen Affinity of Sickle Hemoglobin
Hematology/Oncology Clinics of North America, 2014 The fundamental pathophysiology of sickle cell disease involves the polymerization of sickle hemoglobin in its T-state which develops under low oxygen saturation.
M. Safo, G. Kato
semanticscholar +1 more source